GlobeNewswire Inc | Mar 18, 2021 04:05PM EDT

March 18, 2021

NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on March 25, 2021, to provide a corporate update and review the Companys financial results for the quarter and year ended December 31, 2020.

To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 8599904. A live audio webcast will be accessible from the Investors & News section on the Companys website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Companys website following the event.

AboutTrevi Therapeutics, Inc.Trevi Therapeutics, Inc.is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.Treviis conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinsons disease and is in the planning stages of a Phase 2 study in this indication. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Founded in 2011,Trevi Therapeuticsis headquartered inNew Haven, CT.

About HADUVIOHaduvio is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed -opioid receptor agonist and -opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years inthe United StatesandEurope. The - and -opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphines mechanism of action also mitigates the risk of abuse associated with -opioid agonists because it antagonizes, or blocks, -opioid receptors. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance inthe United Statesand most ofEurope.Treviintends to propose Haduvio as the trade name for the nalbuphine ER investigational product. Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Investor ContactEric RibnerLifeSci Advisors917 592 0932Eric@lifesciadvisors.com

Media Contact Rosalia Scampoli914-815-1465rscampoli@marketcompr.com